Over two decades from the first publication of the Hallmarks of Cancer, proposed in the millennium by Douglas Hanahan and Robert Weinberg, the landscape of cancer research has changed significantly. In 2010, a total of ten hallmarks (six established and four emerging) were solidified to provide a set of criteria to describe how normal, healthy cells can eventually transform to malignant tumors through a successive number of emerging characteristics.
Over time, the field has accepted that tumors are comprised of a plethora of heterogenic cell types, interacting and communicating to build resistance against therapies, innate defense mechanisms and drive proliferation. Furthermore, it is more thoroughly understood how exactly the tumor microenvironment influences disease progression and clinical outcomes, something the more recent hallmarks contribute significantly to. By understanding such processes and integrating the interactions they form with novel therapeutics, we can develop a deeper understanding of how mutagenic cells form and survive.
At Frontiers, we would like to commemorate the incredible research and advancements made surrounding these principles over the last decade by introducing this special series hosted by Frontiers in Oncology. By collecting pioneering research focusing on these principles, we hope to allow for Open Access platforms to drive the next decade of change and technological growth within the oncology field.
With this initiative, we aim to focus on the many aspects involved in cancer diagnosis and treatment and build on our understanding of how they all fit together in the context of the Hallmarks of Cancer. Furthermore, we wish to explore recent research in the emerging hallmarks, while simultaneously horizon scanning and looking to the future of where this might take us.
Hallmark of Cancer: Evasion of Growth Suppressors
Crucial to the health of normal cells is the efficiency and regulation of tumor suppressor genes that act to negatively regulate growth signals and inhibit cell division. Malignant tissue arises when these cellular signaling pathways become constitutively activated or overexpressed and crucially start to suppress or evade the tumor suppressor genes. For example, over 50% to 60% of cancers acquire at some point the inactivation of p53 suggesting that a key part of cancer progression lies in the inability of cells to inhibit their growth. Understanding this hallmark is crucial to our understanding of how cells regulate their growth signals and what we can do to target these processes for therapy.
This Research Topic welcomes high-quality Original Research, Review, and Perspective articles focusing on the growth suppressors plays in cancer. From effects and outcomes to present and future targeted therapeutics. We aim to celebrate the advances made within the last ten years and the many to come.
See below for other collections in the Hallmarks series:
Hallmark of Cancer: Avoiding Immune SuppressionHallmark of Cancer: Genomic Instability and MutationsHallmark of Cancer: Resisting Cell DeathHallmark of Cancer: Sustained ProliferativeHallmark of Cancer: Inducing Angiogenesis Hallmark of Cancer: Replicative ImmortalityHallmark of Cancer: Evasion of Growth SuppressorsHallmark of Cancer: Reprogramming of Cellular MetabolismHallmark of Cancer: Activating Invasion and MetastasisHallmark of Cancer: Tumor Promoting InflammationPlease note: manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
